Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels
Metabolic syndrome (MS) is a disease with an inflammatory component. Telmisartan improves insulin resistance in MS, but its relationship with the inflammatory state is unknown. We investigated the effect of 3-month telmisartan therapy on homeostatic model assessment-insulin resistance (HOMA-IR) in h...
Gespeichert in:
| Veröffentlicht in: | Journal of investigative medicine 2011-03, Vol.59 (3), p.602-605 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 3 |
| container_start_page | 602 |
| container_title | Journal of investigative medicine |
| container_volume | 59 |
| creator | Sanchez Muñoz-Torrero, Juan Francisco Rivas, Maria D. Costo, Alberto Crespo, Leandro Fraile, Juana Doncel, Carlos Fernandez Toro, Jose Maria Zamorano, Jose |
| description | Metabolic syndrome (MS) is a disease with an inflammatory component. Telmisartan improves insulin resistance in MS, but its relationship with the inflammatory state is unknown. We investigated the effect of 3-month telmisartan therapy on homeostatic model assessment-insulin resistance (HOMA-IR) in hypertensive subjects with MS with regard to the levels of circulating plasma cytokines.MethodsA total of 42 patients were included in this study; 30 were men (71%), aged 50 ± 8.2 years (mean ± SD). Cytokines and metabolic parameters were analyzed before and after treatment with telmisartan.ResultsTwenty-eight patients showed low plasma levels of cytokines (group 1) similar to control subjects, and 14 showed high levels (group 2). Treatment with telmisartan diminished by 35% HOMA-IR in group 1 (4.5 ± 3.1 vs 2.9 ± 2.1), without improvement in group 2. In the multivariate analysis, the predictors of improvement of HOMA-IR in response to telmisartan treatment were low levels of cytokines, whereas systolic and diastolic blood pressure and the elevation of high-sensitivity C-reactive protein had a negative effect.ConclusionsOur study provides evidence of a more favorable effect of telmisartan on glucose homeostasis in patients with MS and low levels of serum cytokines. |
| doi_str_mv | 10.2310/JIM.0b013e31820bf26b |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_852905008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.2310_JIM.0b013e31820bf26b</sage_id><sourcerecordid>852905008</sourcerecordid><originalsourceid>FETCH-LOGICAL-b416t-2fdb8a987f89da6e2229e527fedc6a699d5ef57dea68ef456621db9129dbd2d3</originalsourceid><addsrcrecordid>eNqNkN1LwzAUxYMobn78ByIFH3zqltw2afIow49JRZGBjyVZbrWzH7Nplf33RjZF9iA-5Yb8zsm5h5ATRkcQMTq-nd6NqKEswohJoCYHYXbIkCVUhhJEsutnKlnIuVQDcuDcglIQXME-GQCDmCcJDEk6w7IqnG47XQfTatk27-iCae36sqiDR3SF8y9zDPztQXcF1p0LnoruJUibj2Cy6prXosYgxXcs3RHZy3Xp8HhzHpLZ1eVschOm99fTyUUampiJLoTcGqmVTHKprBYIAAo5JDnaudBCKcsx54lFLSTmMRcCmDWKgbLGgo0Oyfna1qd969F1md9gjmWpa2x6l0kOinJKpSfPtshF07e1z5axRAoV8VjEnorX1LxtnGsxz5ZtUel2lTGafXWd-a6z7a697HRj3psK7Y_ou1wPsDXg9DP--vlv0_FaY6rF_2J8AslamRc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786935464</pqid></control><display><type>article</type><title>Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Sanchez Muñoz-Torrero, Juan Francisco ; Rivas, Maria D. ; Costo, Alberto ; Crespo, Leandro ; Fraile, Juana ; Doncel, Carlos ; Fernandez Toro, Jose Maria ; Zamorano, Jose</creator><creatorcontrib>Sanchez Muñoz-Torrero, Juan Francisco ; Rivas, Maria D. ; Costo, Alberto ; Crespo, Leandro ; Fraile, Juana ; Doncel, Carlos ; Fernandez Toro, Jose Maria ; Zamorano, Jose</creatorcontrib><description>Metabolic syndrome (MS) is a disease with an inflammatory component. Telmisartan improves insulin resistance in MS, but its relationship with the inflammatory state is unknown. We investigated the effect of 3-month telmisartan therapy on homeostatic model assessment-insulin resistance (HOMA-IR) in hypertensive subjects with MS with regard to the levels of circulating plasma cytokines.MethodsA total of 42 patients were included in this study; 30 were men (71%), aged 50 ± 8.2 years (mean ± SD). Cytokines and metabolic parameters were analyzed before and after treatment with telmisartan.ResultsTwenty-eight patients showed low plasma levels of cytokines (group 1) similar to control subjects, and 14 showed high levels (group 2). Treatment with telmisartan diminished by 35% HOMA-IR in group 1 (4.5 ± 3.1 vs 2.9 ± 2.1), without improvement in group 2. In the multivariate analysis, the predictors of improvement of HOMA-IR in response to telmisartan treatment were low levels of cytokines, whereas systolic and diastolic blood pressure and the elevation of high-sensitivity C-reactive protein had a negative effect.ConclusionsOur study provides evidence of a more favorable effect of telmisartan on glucose homeostasis in patients with MS and low levels of serum cytokines.</description><identifier>ISSN: 1081-5589</identifier><identifier>EISSN: 1708-8267</identifier><identifier>DOI: 10.2310/JIM.0b013e31820bf26b</identifier><identifier>PMID: 21245772</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Benzimidazoles - pharmacology ; Benzimidazoles - therapeutic use ; Benzoates - pharmacology ; Benzoates - therapeutic use ; Biomarkers - blood ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Cytokines - blood ; Female ; Humans ; Hypertension - blood ; Hypertension - drug therapy ; Insulin resistance ; Insulin Resistance - physiology ; Male ; Metabolic Syndrome - blood ; Metabolic Syndrome - drug therapy ; Middle Aged</subject><ispartof>Journal of investigative medicine, 2011-03, Vol.59 (3), p.602-605</ispartof><rights>2015 American Federation for Medical Research, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2011 American Federation for Medical Research</rights><rights>Copyright: 2015 (c) 2015 American Federation for Medical Research, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b416t-2fdb8a987f89da6e2229e527fedc6a699d5ef57dea68ef456621db9129dbd2d3</citedby><cites>FETCH-LOGICAL-b416t-2fdb8a987f89da6e2229e527fedc6a699d5ef57dea68ef456621db9129dbd2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.2310/JIM.0b013e31820bf26b$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.2310/JIM.0b013e31820bf26b$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,21801,27906,27907,43603,43604</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21245772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchez Muñoz-Torrero, Juan Francisco</creatorcontrib><creatorcontrib>Rivas, Maria D.</creatorcontrib><creatorcontrib>Costo, Alberto</creatorcontrib><creatorcontrib>Crespo, Leandro</creatorcontrib><creatorcontrib>Fraile, Juana</creatorcontrib><creatorcontrib>Doncel, Carlos</creatorcontrib><creatorcontrib>Fernandez Toro, Jose Maria</creatorcontrib><creatorcontrib>Zamorano, Jose</creatorcontrib><title>Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels</title><title>Journal of investigative medicine</title><addtitle>J Investig Med</addtitle><description>Metabolic syndrome (MS) is a disease with an inflammatory component. Telmisartan improves insulin resistance in MS, but its relationship with the inflammatory state is unknown. We investigated the effect of 3-month telmisartan therapy on homeostatic model assessment-insulin resistance (HOMA-IR) in hypertensive subjects with MS with regard to the levels of circulating plasma cytokines.MethodsA total of 42 patients were included in this study; 30 were men (71%), aged 50 ± 8.2 years (mean ± SD). Cytokines and metabolic parameters were analyzed before and after treatment with telmisartan.ResultsTwenty-eight patients showed low plasma levels of cytokines (group 1) similar to control subjects, and 14 showed high levels (group 2). Treatment with telmisartan diminished by 35% HOMA-IR in group 1 (4.5 ± 3.1 vs 2.9 ± 2.1), without improvement in group 2. In the multivariate analysis, the predictors of improvement of HOMA-IR in response to telmisartan treatment were low levels of cytokines, whereas systolic and diastolic blood pressure and the elevation of high-sensitivity C-reactive protein had a negative effect.ConclusionsOur study provides evidence of a more favorable effect of telmisartan on glucose homeostasis in patients with MS and low levels of serum cytokines.</description><subject>Adult</subject><subject>Benzimidazoles - pharmacology</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Benzoates - pharmacology</subject><subject>Benzoates - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Cytokines - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - blood</subject><subject>Hypertension - drug therapy</subject><subject>Insulin resistance</subject><subject>Insulin Resistance - physiology</subject><subject>Male</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - drug therapy</subject><subject>Middle Aged</subject><issn>1081-5589</issn><issn>1708-8267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkN1LwzAUxYMobn78ByIFH3zqltw2afIow49JRZGBjyVZbrWzH7Nplf33RjZF9iA-5Yb8zsm5h5ATRkcQMTq-nd6NqKEswohJoCYHYXbIkCVUhhJEsutnKlnIuVQDcuDcglIQXME-GQCDmCcJDEk6w7IqnG47XQfTatk27-iCae36sqiDR3SF8y9zDPztQXcF1p0LnoruJUibj2Cy6prXosYgxXcs3RHZy3Xp8HhzHpLZ1eVschOm99fTyUUampiJLoTcGqmVTHKprBYIAAo5JDnaudBCKcsx54lFLSTmMRcCmDWKgbLGgo0Oyfna1qd969F1md9gjmWpa2x6l0kOinJKpSfPtshF07e1z5axRAoV8VjEnorX1LxtnGsxz5ZtUel2lTGafXWd-a6z7a697HRj3psK7Y_ou1wPsDXg9DP--vlv0_FaY6rF_2J8AslamRc</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Sanchez Muñoz-Torrero, Juan Francisco</creator><creator>Rivas, Maria D.</creator><creator>Costo, Alberto</creator><creator>Crespo, Leandro</creator><creator>Fraile, Juana</creator><creator>Doncel, Carlos</creator><creator>Fernandez Toro, Jose Maria</creator><creator>Zamorano, Jose</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AM</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGRYB</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K7.</scope><scope>K9.</scope><scope>M0O</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels</title><author>Sanchez Muñoz-Torrero, Juan Francisco ; Rivas, Maria D. ; Costo, Alberto ; Crespo, Leandro ; Fraile, Juana ; Doncel, Carlos ; Fernandez Toro, Jose Maria ; Zamorano, Jose</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b416t-2fdb8a987f89da6e2229e527fedc6a699d5ef57dea68ef456621db9129dbd2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Benzimidazoles - pharmacology</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Benzoates - pharmacology</topic><topic>Benzoates - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Cytokines - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - blood</topic><topic>Hypertension - drug therapy</topic><topic>Insulin resistance</topic><topic>Insulin Resistance - physiology</topic><topic>Male</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - drug therapy</topic><topic>Middle Aged</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez Muñoz-Torrero, Juan Francisco</creatorcontrib><creatorcontrib>Rivas, Maria D.</creatorcontrib><creatorcontrib>Costo, Alberto</creatorcontrib><creatorcontrib>Crespo, Leandro</creatorcontrib><creatorcontrib>Fraile, Juana</creatorcontrib><creatorcontrib>Doncel, Carlos</creatorcontrib><creatorcontrib>Fernandez Toro, Jose Maria</creatorcontrib><creatorcontrib>Zamorano, Jose</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Criminal Justice Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Criminology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Criminal Justice (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Criminal Justice</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez Muñoz-Torrero, Juan Francisco</au><au>Rivas, Maria D.</au><au>Costo, Alberto</au><au>Crespo, Leandro</au><au>Fraile, Juana</au><au>Doncel, Carlos</au><au>Fernandez Toro, Jose Maria</au><au>Zamorano, Jose</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels</atitle><jtitle>Journal of investigative medicine</jtitle><addtitle>J Investig Med</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>59</volume><issue>3</issue><spage>602</spage><epage>605</epage><pages>602-605</pages><issn>1081-5589</issn><eissn>1708-8267</eissn><abstract>Metabolic syndrome (MS) is a disease with an inflammatory component. Telmisartan improves insulin resistance in MS, but its relationship with the inflammatory state is unknown. We investigated the effect of 3-month telmisartan therapy on homeostatic model assessment-insulin resistance (HOMA-IR) in hypertensive subjects with MS with regard to the levels of circulating plasma cytokines.MethodsA total of 42 patients were included in this study; 30 were men (71%), aged 50 ± 8.2 years (mean ± SD). Cytokines and metabolic parameters were analyzed before and after treatment with telmisartan.ResultsTwenty-eight patients showed low plasma levels of cytokines (group 1) similar to control subjects, and 14 showed high levels (group 2). Treatment with telmisartan diminished by 35% HOMA-IR in group 1 (4.5 ± 3.1 vs 2.9 ± 2.1), without improvement in group 2. In the multivariate analysis, the predictors of improvement of HOMA-IR in response to telmisartan treatment were low levels of cytokines, whereas systolic and diastolic blood pressure and the elevation of high-sensitivity C-reactive protein had a negative effect.ConclusionsOur study provides evidence of a more favorable effect of telmisartan on glucose homeostasis in patients with MS and low levels of serum cytokines.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>21245772</pmid><doi>10.2310/JIM.0b013e31820bf26b</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1081-5589 |
| ispartof | Journal of investigative medicine, 2011-03, Vol.59 (3), p.602-605 |
| issn | 1081-5589 1708-8267 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_852905008 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Benzoates - pharmacology Benzoates - therapeutic use Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Cytokines - blood Female Humans Hypertension - blood Hypertension - drug therapy Insulin resistance Insulin Resistance - physiology Male Metabolic Syndrome - blood Metabolic Syndrome - drug therapy Middle Aged |
| title | Telmisartan Improves Insulin Resistance in Patients With Low Cytokine Levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A08%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telmisartan%20Improves%20Insulin%20Resistance%20in%20Patients%20With%20Low%20Cytokine%20Levels&rft.jtitle=Journal%20of%20investigative%20medicine&rft.au=Sanchez%20Mu%C3%B1oz-Torrero,%20Juan%20Francisco&rft.date=2011-03-01&rft.volume=59&rft.issue=3&rft.spage=602&rft.epage=605&rft.pages=602-605&rft.issn=1081-5589&rft.eissn=1708-8267&rft_id=info:doi/10.2310/JIM.0b013e31820bf26b&rft_dat=%3Cproquest_cross%3E852905008%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1786935464&rft_id=info:pmid/21245772&rft_sage_id=10.2310_JIM.0b013e31820bf26b&rfr_iscdi=true |